Tagged with M

Germany The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered are Merck KGaA’s tie-up with JSR Life Sciences for its chromatography business, Bayer’s 12,000 layoffs, and STADA’s potential IPO.  …

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive HER2 ADC Phase III data, Biokin’s US$250 million milestone payment from BMS and HKEX IPO approval, and Haixi Pharma’s 36%…

Taiwan Dr Wen-Liang Huang, General Manager of Ever Supreme Biotechnology, brings over 40 years of clinical cardiology experience to biopharmaceutical leadership. Recruited by the company’s founder, his medical background informs the translation of cell therapy innovations into meaningful patient treatments. Under his guidance, Ever Supreme has become Taiwan’s pioneering cell therapy…

USA Norman Stoffregen, SVP and Site Head at Enzene Inc., explains how the US arm of India’s Enzene Biosciences is introducing its cost-efficient, continuous manufacturing model to the US CDMO market. With a state-of-the-art facility in Hopewell, New Jersey, Enzene supports mid-sized biopharma clients with flexible, small-footprint biologics production. By combining…

USA Thomas Nusbickel, Chief Commercial Officer, describes how Celltrion, founded over 20 years ago, pioneered biosimilars through a fully integrated business model. Its US office opened in 2018 and has since transitioned from partnerships to direct sales, launching several biosimilars in oncology, immunology and endocrinology. With a strong pipeline, a growing…

USA The latest updates from the US healthcare and life sciences scene. Eli Lilly partners with Nvidia to build a supercomputer for faster drug discovery; Trump secures “most-favored-nation” pricing deals with AstraZeneca and EMD Serono; former FDA vaccine chief Peter Marks joins Lilly to head infectious diseases; Organon CEO Kevin Ali…

Pharma Legal Handbook 1.Please make a general introduction to the public health sector in your country and its organization Saudi Arabia provides universal health coverage primarily funded by the government through a tax-based model. The healthcare system is organized in a tiered structure led by the Ministry of Health (MOH), which operates: •…

Pharma Legal Handbook Which are the administrations, bodies and institutions in charge of public health in your country and what are their respective responsibilities? The Ministry of Health (MOH) is the primary body responsible for public health in Saudi Arabia. It sets national health policies, issues licenses to healthcare providers (public and private),…

Pharma Legal Handbook What are the pricing models, processes and principles for originator drugs? Originator drugs (innovator medicines) are priced by the Saudi Food and Drug Authority (SFDA) following the principles outlined in its 2023 Drug Pricing Guidelines. The pricing process includes: External Reference Pricing (ERP): SFDA compares prices with a reference basket…

Pharma Legal Handbook What are the pricing models, processes and principles for originator drugs? Drugs are provided by a medical institution or pharmacy to a patient based on the NHI Drug Price (a patient pays 10%, 20% or 30% (depending on age and other conditions) of the NHI Drug Price). As detailed in…

Pharma Legal Handbook Have local authorities published recommendations surrounding value assessment dossiers? (If yes please add link) Yes. The SFDA published the Economic Evaluation Studies Guideline (PDF, July 10, 2024), which outlines comprehensive methods and includes a checklist. Followed by the Pharmacoeconomic Submission Portal Manual (January 2025), detailing dossier preparation and submission protocols.…

Pharma Legal Handbook In addition to the clinical data obtained through clinical studies please list the data required for   a. Market approval In addition to clinical trial data, the following documents are required for market authorization in Saudi Arabia: Quality/CMC Module: Includes full GMP certificates (PIC/S or WHO type) and a local…